Galena Biopharma Reports Positive Outcome from the Data Safety Monitoring Board on the Two NeuVax™ (nelipepimut-S) Clinical...
February 06 2017 - 7:05AM
Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company
committed to the development and commercialization of hematology
and oncology therapeutics that address unmet medical needs, today
announced the results from a meeting of the Data Safety Monitoring
Board (DSMB) for the two investigator-sponsored (IST) combination
clinical trials with NeuVax™ (nelipepimut-S) plus
trastuzumab. The trials are being run in breast cancer
patients to assess the ability of the combination of trastuzumab
and the HER2 vaccine nelipepimut-S (administered with the
immunoadjuvant granulocyte macrophage-colony stimulating factor) to
prevent recurrence in the adjuvant setting.
In light of the early termination of the NeuVax Phase 3 PRESENT
(Prevention of Recurrence in
Early-Stage, Node-Positive Breast
Cancer with Low to Intermediate HER2 Expression
with NeuVax Treatment) trial last
year, the independent DSMB performed separate futility assessments
on each of the NeuVax plus trastuzumab combination trials.
The DSMB reported that there are no safety concerns with
either trial and neither was found to be futile.
For the Phase 2b trial in patients with low-to-intermediate HER2
expression (HER2 1+/2+), n=242 patients were evaluated, and the
recommendation from the DSMB is to continue the trial with one
revision to the statistical analysis plan regarding the timing of
the pre-specified interim analysis. Given the lengthy duration of
enrollment for the trial, the DSMB determined that the
pre-specified interim efficacy analysis be moved up from 12 months
to 6 months after the last patient is enrolled. Completion of
enrollment is expected in the second quarter of 2017; therefore,
the DSMB expects to perform the interim efficacy analysis near the
end of 2017.
For the Phase 2 trial in high-risk, HER2 3+ patients, and per
the trial protocol, the pre-specified interim safety analysis was
also completed on n=50 patients and demonstrated that the agent is
well tolerated with no increased cardiotoxicity associated
with giving NeuVax in combination with trastuzumab. These
findings were similar to the findings presented in October 2016
from the HER2 1+/2+ trial. The recommendation from the DSMB is to
continue the HER2 3+ trial unmodified.
“The recommendations from the DSMB are very positive for NeuVax
in combination with trastuzumab as there were no safety concerns
and the studies were not deemed futile. Given these findings,
the trials can continue per the DSMB recommendation,” said Bijan
Nejadnik, M.D., Executive Vice President and Chief Medical
Officer. “We are also pleased that we will be able to reach
the interim efficacy analysis in our Phase 2b HER2 1+/2+ trial
earlier than expected with that readout now planned by the end of
this year. It is important to note that these IST trials are
designed with a different methodology to identify recurrences
clinically and not via proactive imaging as was done in the PRESENT
trial. We are grateful to our investigators running these
trials and their continued dedication to breast cancer patients as
they study potential new therapeutic options to prevent
recurrence.”
About NeuVax™ (nelipepimut-S)
NeuVax™ (nelipepimut-S) is a first-in-class, HER2-directed
cancer immunotherapy under evaluation to prevent breast cancer
recurrence after standard of care treatment in the adjuvant
setting. NeuVax contains the immunodominant peptide derived
from the extracellular domain of the HER2 protein, a
well-established target for therapeutic intervention in breast
carcinoma. The nelipepimut-S sequence stimulates specific CD8+
cytotoxic T lymphocytes (CTLs) following binding to specific HLA
molecules on antigen presenting cells (APC). These activated
specific CTLs recognize, neutralize and destroy, through cell
lysis, HER2 expressing cancer cells, including occult cancer cells
and micrometastatic foci. The nelipepimut-S immune response can
also generate CTLs to other immunogenic peptides through inter- and
intra-antigenic epitope spreading. In clinical studies,
NeuVax is combined with recombinant granulocyte macrophage-colony
stimulating factor (GM-CSF).
NeuVax is currently in two breast cancer studies in combination
with trastuzumab (Herceptin®; Genentech/Roche): a Phase 2b trial in
node positive and triple negative HER2 IHC 1+/2+
(clinicaltrials.gov identifier: NCT01570036); and, a Phase 2 trial
in high risk, node positive or negative HER2 IHC 3+ patients
(clinicaltrials.gov identifier: NCT02297698). A Phase 2
clinical trial is also ongoing with NeuVax in patients with ductal
carcinoma in situ (DCIS) (clinicaltrials.gov identifier:
NCT02636582), and a Phase 2 trial is planned in patients with
gastric cancer.
About Breast Cancer1
New cases of breast cancer occur at an annual rate of 125 per
100,000 women in the U.S., with an estimated 246,660 new cases and
40,450 deaths in 2016. Approximately 89.7% of breast cancer
patients are expected to survive five years after diagnosis.
Approximately 12.4% of women will be diagnosed with breast cancer
at some point during their lifetime (2011 – 2013 data). Of
the women diagnosed with breast cancer annually, about 25% are HER2
positive (IHC 3+) and approximately 50%-60% of these women express
HER2 at a low to intermediate range (IHC 1+/2+ or FISH < 2.0).
The prevalence data from 2013 showed an estimated 3,053,450 women
living with breast cancer in the United States.
1National Cancer Institute Surveillance, Epidemiology, and End
Results Program
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed
to the development and commercialization of hematology and oncology
therapeutics that address unmet medical needs. Galena’s pipeline
consists of multiple mid-to-late-stage clinical assets led by its
hematology asset, GALE-401, and its novel cancer immunotherapy
programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302.
For more information, visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the development of Galena’s
product candidates, patient enrollment in our clinical trials, as
well as other statements related to the progress and timing of our
development activities, Galena’s current and prospective financial
condition, liquidity and access to capital, present or future
licensing, collaborative or financing arrangements, expected
outcomes with regulatory agencies, and projected market
opportunities for product candidates or that otherwise relate to
future periods. These forward-looking statements are subject to a
number of risks, uncertainties and assumptions, including those
identified under “Risk Factors” in Galena’s Annual Report on Form
10-K for the year ended December 31, 2015 and most recent Quarterly
Reports on Form 10-Q and current reports on Form 8-K filed with the
SEC. Actual results may differ materially from those contemplated
by these forward-looking statements. Galena does not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
of this press release.
NeuVax is a trademark of Galena Biopharma, Inc.
Source: Galena Biopharma, Inc.
Contact:
Remy Bernarda
SVP, Investor Relations & Corporate Communications
(925) 498-7709
ir@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024